Selected Publication:
SHR
Neuro
Cancer
Cardio
Lipid
Metab
Microb
Scheipl, S; Igrec, J; Leithner, A; Smolle, M; Haybäck, J; Liegl, B.
[Chordoma: is there a molecular basis for diagnosis and treatment?].
Pathologe. 2020; 41(2):153-162
Doi: 10.1007/s00292-020-00761-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
-
Scheipl Susanne
- Co-authors Med Uni Graz
-
Haybäck Johannes
-
Igrec Jasminka
-
Leithner Andreas
-
Liegl-Atzwanger Bernadette
-
Smolle Maria Anna
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
Chordomas are malignant bone tumours with a reported annual incidence of 0.08 per 100,000 cases. They show a notochordal differentiation and are characterised by their nuclear expression of brachyury (TBXT). Chordomas are localised in the axial skeleton, where they occur from the clivus to the sacrococcygeal region. They are slow growing, locally destructive tumours, and are often not diagnosed until they have reached an advanced stage. Putative precursor-lesions are benign notochordal cell lesions, which are microscopically small and intraosseous. Different histological chordoma subtypes exist, which differ in their prognosis. To date, there are no known recurrent genetic drivers for this disease. Brachyury seems to play a key role in the pathogenesis of chordoma, though the detailed mechanism still needs to be elucidated. Surgical en bloc resection with negative margins is the only curative treatment for this disease. High-dose irradiation, particularly with protons and carbon ions, is a therapeutic alternative in cases of inoperable tumours. Currently, there is no approved medical treatment for chordoma. Clinical trials exploring additional therapeutic modalities are ongoing.
- Find related publications in this database (Keywords)
-
TBXT
-
INI1
-
Classic chordoma
-
Chondroid chordoma
-
Poorly differentiated chordoma
-
Dedifferentiated chordoma
-
Heavy ion irradiation
-
En-bloc resection